English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration

MPS-Authors
/persons/resource/persons147178

Grefkes,  Christian
Neuromodulation und Neurorehabilitation, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

External Ressource
No external resources are shared
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Hermann, M. M., van Asten, F., Muether, P. S., Smailhodzic, D., Lichtner, P., Hoyng, C. B., et al. (2014). Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration. Ophthalmology, 121(4), 905-910. doi:10.1016/j.ophtha.2013.10.047.


Cite as: http://hdl.handle.net/11858/00-001M-0000-0026-D836-D
Abstract
© 2014 American Academy of Ophthalmology.